Secondly, Rahman et al. [92] related an up-regulation of CRY2 in patients with the relapse of AML in patients with 3 months of chemotherapy for CML. This evidence concerns the gene CRY2 and chronic myelogenous leukemia, BCR-ABL1 positive.